Management of Malignant Phyllodes Tumors

Diagnosis and Classification

Phyllodes tumors are classified into three histologic subtypes based on stromal features, with 5-year disease-free survival rates of 95.7% for benign, 73.7% for borderline, and 66.1% for malignant tumors 1

The American College of Surgeons recommends surgical excision with tumor-free margins of ≥1 cm as the single most important factor for preventing local recurrence in phyllodes tumors 1
The National Comprehensive Cancer Network suggests that lumpectomy or partial mastectomy is the preferred surgical approach for phyllodes tumors 1
Total mastectomy is indicated only if negative margins cannot be achieved with breast-conserving surgery, as recommended by the Society of Surgical Oncology 1
Axillary lymph node dissection or sentinel node biopsy is not indicated because phyllodes tumors rarely metastasize to lymph nodes (<1% have positive nodes), according to the American Society of Clinical Oncology 1

The European Society for Medical Oncology recommends that radiotherapy is not routinely recommended for all phyllodes tumors, but may be considered for malignant tumors >5 cm in size, infiltrative margins, or cases where clear margins could not be achieved despite re-excision attempts 1
The American Society of Clinical Oncology states that neither chemotherapy nor endocrine therapy has any proven role in the adjuvant treatment of phyllodes tumors 1, 2, 3

The National Comprehensive Cancer Network recommends that for metastatic disease, surgical resection or local ablative therapy of metastatic lesions should be the primary treatment approach given the relatively indolent nature of these tumors 2, 3
The European Society for Medical Oncology suggests that when surgery is not possible or after disease progression, use sarcoma-directed chemotherapy regimens, such as the Doxorubicin-Ifosfamide (AI) regimen, and not breast cancer protocols 2, 3

The American College of Surgeons advises against using breast cancer chemotherapy regimens for phyllodes tumors 4, 2, 3
The Society of Surgical Oncology recommends against prescribing tamoxifen, aromatase inhibitors, or other endocrine therapy for phyllodes tumors, as they have no proven efficacy despite hormone receptor positivity 1, 2, 3